# Problem Statement

## Background

Clinical trials are the cornerstone of modern medicine, validating the safety and efficacy of novel therapeutics before regulatory approval. A typical Phase III clinical trial spans dozens or hundreds of investigative sites globally, involves thousands of randomized participants, and generates tens of thousands of protocol visit records. To ensure data reliability and patient safety, trials operate under strict Good Clinical Practice (GCP) guidelines (ICH E6 R2) and comprehensive, versioned clinical protocols.

## The Problem

Despite rigorous protocol specifications, clinical research sites frequently commit protocol deviations:
1. **Dosing Inaccuracies**: Participants receive incorrect investigational product (IP) doses or uncalibrated dose adjustments.
2. **Visit Window Violations**: Patient appointments occur outside predefined tolerance windows (e.g. Day 14 ± 2 days), compromising pharmacokinetics/pharmacodynamics (PK/PD) assessments.
3. **Missed Visits**: Participants skip critical safety monitoring visits without prompt site escalation.
4. **Prohibited Concomitant Medications**: Participants take unapproved co-medications that confound drug interaction profiles.
5. **Documentation Deficits**: Source records omit dose verification, vital signs, or laboratory reports.

Clinical Operations (ClinOps) teams, Clinical Research Associates (CRAs), and Medical Monitors currently rely on manual spreadsheet tracking and retrospective batch reports that surface issues weeks or months after visits take place. By that time, systemic process failures at struggling sites have already multiplied.

## Who is Affected

- **Clinical Research Associates (CRAs / Monitors)**: Field monitors visiting study sites who lack prioritized leading indicators of which sites need urgent intervention.
- **Clinical Operations Leaders & Study Directors**: Trial managers responsible for overall study timeline, budget, and regulatory submission milestones across 50–200+ global research sites.
- **Quality Assurance & Regulatory Affairs**: Officers tasked with compiling GCP compliance packages and resolving inspection queries under FDA / EMA scrutiny.
- **Trial Participants**: Patients whose safety depends on adherence to experimental dosing regimens and timely adverse event monitoring.

## Why It Matters

- **Regulatory Rejections & Inspection Findings**: Protocol deviations are the leading cause of Form FDA 483 inspection observations, Warning Letters, and delayed drug marketing approvals.
- **Patient Safety Compromise**: Administering 75 mg instead of 50 mg (+50% overdose) or failing to catch prohibited co-medications poses immediate toxicity risks to participants.
- **Enormous Financial Waste**: The average cost to remediate a critical audit finding or repeat a compromised clinical trial cohort ranges from $1M to $25M+, alongside irreversible market delays.

## Why Existing Solutions Fall Short

Traditional Electronic Data Capture (EDC) systems and Clinical Trial Management Systems (CTMS) function as transactional silos. They store data passively without executing continuous, multi-dimensional protocol rule validation. Data managers must write complex ad-hoc SQL queries or wait for periodic data lock reviews to uncover deviations. Furthermore, legacy tools do not synthesize multi-factor risk scores (combining deviation count, overdue queries, staff training gaps, and visit adherence) into actionable, auditable Corrective and Preventive Action (CAPA) plans.
